Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hyperkalemic periodic paralysis (HyperPP) is a muscle disorder characterized by episodic attacks of muscle weakness associated with an increase in serum potassium concentration.
Features include common findings: Myotonia. 5 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 2 | Episodic flaccid weakness, Myotonia |
The attacks of flaccid muscle weakness associated with hyperkalemic periodic paralysis (hyperPP) usually begin in the first decade of life and increase in frequency and severity over time, with 25% experiencing their sentinel attack in the second decade of life. Initially infrequent, the attacks increase in frequency and severity over time until approximately age 50 years, after which the frequency declines considerably. Triggers include cold environment; rest after exercise, stress, or fatigue; alcohol; hunger; changes in activity level; potassium in food; specific foods or beverages; changes in humidity; extra sleep; pregnancy; illness of any type; menstruation; medication; and potassium supplements . The major attack trigger is eating potassium-rich foods.
Source: GeneReviews — "Hyperkalemic Periodic Paralysis"
SCN4A function has not been fully characterized.
Hyperkalemic periodic paralysis is associated with mutations in the SCN4A gene on chromosome 17.
No genotype-phenotype correlations have been identified.
Source: GeneReviews — "Hyperkalemic Periodic Paralysis"
Usually, the penetrance is high (90%). A few individuals with rare heterozygous pathogenic variants do not present with clinically detectable symptoms but have signs of myotonia detectable by EMG only .
Source: GeneReviews — "Hyperkalemic Periodic Paralysis"
Hyperkalemic periodic paralysis (hyperPP) should be suspected in individuals with the following family history and clinical, electromyogram, and suggestive laboratory findings:
Clinical findings
History of at least two attacks of flaccid limb weakness (which may also include weakness of the muscles of the eyes, throat, breathing muscles, and trunk)
Onset or worsening of an attack as a result of oral potassium intake
Disease manifestations before age 20 years
Absence of cardiac arrhythmia between attacks
Normal psychomotor development
Family history
Typically, at least one affected first-degree relative
Note: Absence of a family history suggestive of hyperPP does not preclude the diagnosis.
Electromyogram (EMG)
Source: GeneReviews — "Hyperkalemic Periodic Paralysis"
In addition to the allelic disorders described in , other conditions with periodic paralysis or with hyperkalemia to consider when making the diagnosis of hyperkalemic periodic paralysis (hyperPP) are discussed below. Adult onset of clinical manifestations points to other diagnoses such as the Andersen-Tawil syndrome or secondary acquired forms of hyperPP. The following signs and symptoms suggest a diagnosis other than hyperPP: • Associated sensory symptoms, including pain or tenderness • Sensory loss could suggest polyneuropathy such as Guillain-Barr syndrome. • Pain could suggest myositis; however, some individuals with hyperPP report paralytic episodes as painful and show symptoms of fibromyalgia . • Urinary retention or constipation, which may be observed in other causes of acute or subacute paralysis, but can occur rarely in hyperPP. (Bowel incontinence and bladder incontinence during attacks are reported in hyperPP.) • Associated symptoms that suggest myasthenia or involvement of the neuromuscular junction, including: • Ptosis (Lid lag myotonia, which may mimic ptosis, may rarely be reported in hyperPP; see .) • Diplopia • Dysphagia (may rarely be reported in hyperPP; see .) • Dysarthria • Alteration or loss of consciousness • Abnormal movement • History of fever days before an attack, which could suggest poliomyelitis or other virus-caused paralysis • History of back pain days before an attack, which could suggest acute transverse myelitis or Guillain-Barr syndrome • History of tick bite, which could suggest tick paralysis The four major differential diagnoses of hyperPP are hypokalemic periodic paralysis (hypoPP), normokalemic potassium-sensitive periodic paralysis (normoPP), thyrotoxic periodic paralysis (TPP), and Andersen-Tawil syndrome (ATS) . HypoPP is the most common cause of periodic paralysis. Table 4. The Different Categories of Periodic Paralyses (PP) with Membrane Excitability Disorder and Associated Findings HypoPP
Genetic testing for SCN4A is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hyperkalemic periodic paralysis has been reported in the published literature.
1 FDA-approved treatment is available for hyperkalemic periodic paralysis, including DICHLORPHENAMIDE (KEVEYIS, approved 1958).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
KEVEYIS | DICHLORPHENAMIDE | — | 1958 | Available |
No clinical practice guidelines for hyperkalemic periodic paralysis (hyperPP) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with hyperkalemic periodic paralysis (hyperPP), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 5. Recommended Evaluations Following Initial Diagnosis in Individuals with Hyperkalemic Periodic Paralysis (hyperPP)
System/Concern | Evaluation | Comment |
|---|---|---|
Genetic counseling | By genetics professionals1 | To inform patients their families re nature, MOI, implications of hyperPP in order to facilitate medical personal decision making MOI = mode of inheritance; STIR = short tau inversion recovery 1. |
Treatment of Manifestations in Individuals with Hyperkalemic Periodic Paralysis (hyperPP) Manifestation/Concern |
Avoid the following:
Opioids or depolarizing agents such as potassium, anticholinesterases, and succinylcholine as part of general anesthesia. These can aggravate a myotonic reaction and induce masseter spasms and stiffness of respiratory muscles, which may impair intubation; mechanical ventilation may also be impaired.
Drugs known as ACE-inhibitors for the treatment of arterial hypertension. These may lead to hyperkalemia as a side effect, especially if they are combined with potassium-sparing diuretics (e.g., spironolactone) and/or renal function is impaired.
Alterations of serum osmolarity, pH, and hypothermia-induced muscle shivering and mechanical stimuli during general anesthesia. These can exacerbate the myotonic reaction in individuals with hyperPP.
See also .
Source: GeneReviews — "Hyperkalemic Periodic Paralysis"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Hyperkalemic Periodic Paralysis"
1 trial found
Table 7. Recommended Surveillance for Individuals with Hyperkalemic Periodic Paralysis (hyperPP)
System/Concern | Evaluation | Frequency |
|---|---|---|
Diuretic-induced hypokalemia1 | Serum potassium concentration (target: between 3.0 3.5 mmol/L) | Every 6 mos |
Muscle weakness | Neurologic exam w/focus on muscle strength in the legs in order to detect permanent weakness | Annually MRI of the leg muscles1 |
Thyroid dysfunction | Thyroid function testing | Annually 1. If on continuous prophylactic diuretic treatment To judge how much normal muscle tissue is preserved and whether edema is present. Na+ MRI is ideal, but only investigational at this time. |
Source: GeneReviews — "Hyperkalemic Periodic Paralysis"
Phenotype severity distribution: 1 common feature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
18 publications have been identified in PubMed for hyperkalemic periodic paralysis. Research spans Review / Meta-Analysis (33%), Case Report / Case Series (22%), and Other (11%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 6 | 33% |
Patient case studies | 4 | 22% |
Other research | 2 | 11% |
Laboratory research | 2 | 11% |
New treatment approaches | 2 | 11% |
Testing and diagnosis research | 1 | 6% |
Disease patterns and progression | 1 | 6% |
Kubota T (2026). [PMID: 41485931](https://pubmed.ncbi.nlm.nih.gov/41485931/). *Nihon Yakurigaku Zasshi*. [Review / Meta-Analysis]
Politano L (2026). [PMID: 41954145](https://pubmed.ncbi.nlm.nih.gov/41954145/). *Acta Myol*. [Review / Meta-Analysis]
McFarlane GR (2026). [PMID: 41866194](https://pubmed.ncbi.nlm.nih.gov/41866194/). *J Reprod Dev*. [Diagnostic / Biomarker]
Haider S (2026). [PMID: 41371188](https://pubmed.ncbi.nlm.nih.gov/41371188/). *Neuromuscul Disord*. [Review / Meta-Analysis]
Sekhon DS (2026). [PMID: 33231989](https://pubmed.ncbi.nlm.nih.gov/33231989/). *Unknown Journal*. [Other]
Shnaiderman-Torban A (2025). [PMID: 38839562](https://pubmed.ncbi.nlm.nih.gov/38839562/). *Vet Ophthalmol*. [Other]
Castro D (2025). [PMID: 39741097](https://pubmed.ncbi.nlm.nih.gov/39741097/). *Vet Clin North Am Equine Pract*. [Review / Meta-Analysis]
Elia N (2025). [PMID: 40138348](https://pubmed.ncbi.nlm.nih.gov/40138348/). *Proc Natl Acad Sci U S A*. [Basic Science / Preclinical]
Brand K (2025). [PMID: 40197299](https://pubmed.ncbi.nlm.nih.gov/40197299/). *BMC Nephrol*. [Case Report / Case Series]
Finno CJ (2025). [PMID: 40122270](https://pubmed.ncbi.nlm.nih.gov/40122270/). *J Equine Vet Sci*. [Review / Meta-Analysis]
Data assembled from 9 of 12 sources · Last updated Sep 19, 2026, 1:00 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
NormoPP |
|---|
HyperPP |
|---|
TPP1 |
|---|
Main clinical features | Weakness episodes lasting hrs to days w/concomitant hypokalemia | Weakness episodes lasting hrs to days w/concomitant normokalemia |
Age at first attacks | Late in 1st decade or in 2nd decade | Late in 1st decade or in 2nd decade |
Main triggers | Rest after exercise, carbohydrate-rich meal, salt intake, stress, cold | Rest after exercise, carbohydrate-rich meal, salt intake, stress, cold |
Source: GeneReviews — "Hyperkalemic Periodic Paralysis"
Treatment |
Considerations/Other |
Attacks of flaccid muscle weakness | Continuing mild exercise /or oral ingestion of carbohydrates (2 g glucose per kg body weight) at onset of weakness | May prevent or abort attacks IV glucocorticoids or inhalation of 2 puffs of 0.1 mg salbutamol |
Myotonia-assoc issues w/general anesthesia2 | An induction sequence incorporating inhalation of oxygen, cricoid pressure, thiopental, 2x the ED95 dose of an intermediate or short-action non-depolarizing muscle relaxant, followed by intubation, is a reasonable approach to securing the airway in persons w/hyperPP. | Avoid opioids or depolarizing agents incl potassium, anticholinesterases, succinylcholine, which can aggravate a myotonic reaction induce masseter spasms stiffness of respiratory muscles. |
Myotonia | Mexiletine has been used to treat myotonia in this disorder . | IV = intravenous 1. One case report suggested that intravenous magnesium is beneficial as well . Because the generalized muscle spasms associated with such attacks may lead to an increase in body temperature, individuals with hyperPP have been considered to be susceptible to malignant hyperthermia. |
Source: GeneReviews — "Hyperkalemic Periodic Paralysis"